Publicacións (135) Publicacións de Luis Pérez de Llano

2024

  1. Basic host response parameters to classify mortality risk in COVID-19 and community-acquired pneumonia

    Scientific reports, Vol. 14, Núm. 1, pp. 12726

  2. Burden of Uncontrolled Severe Asthma With and Without Elevated Type-2 Inflammatory Biomarkers

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 12, Núm. 4, pp. 970-982

  3. Cough severity visual analog scale scores and quality of life in patients with refractory or unexplained chronic cough

    Respiratory Investigation, Vol. 62, Núm. 6, pp. 987-994

  4. Impact of comorbidities on the achievement of specific therapeutic goals in biologic-treated asthma patients

    Allergy: European Journal of Allergy and Clinical Immunology

  5. Impact of the ERS/ATS 2022 Guidelines for Interpretation of Lung Function Test Results When Assessing the Response to Biologics in Asthma

    Journal of Investigational Allergology and Clinical Immunology

2023

  1. Cluster Analyses From the Real-World NOVELTY Study: Six Clusters Across the Asthma-COPD Spectrum

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 9, pp. 2803-2811

  2. Comparative effectiveness of anti-IL5 and anti-IgE biologic classes in patients with severe asthma eligible for both

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 7, pp. 1934-1948

  3. Contribution of the Remission Concept to the Treatment of Asthma

    Archivos de Bronconeumologia

  4. Factors associated with suboptimal response to monoclonal antibodies in severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology

  5. First-Line Versus Second-Line Use of Reslizumab in Severe Uncontrolled Asthma

    Journal of Investigational Allergology and Clinical Immunology

  6. Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 9, pp. 2732-2747

  7. Nocturnal Dyspnea During Severe Exacerbations Is Associated With Mortality Risk in COPD

    Respiratory care, Vol. 68, Núm. 3, pp. 413-416

  8. Quality indicators in the rational management of severe asthma: A Spanish multidisciplinary consensus

    Journal of Healthcare Quality Research, Vol. 38, Núm. 5, pp. 277-283

  9. Redefining the Role of Bronchoscopy in the Workup of Severe Uncontrolled Asthma in the Era of Biologics: A Prospective Study

    Chest, Vol. 164, Núm. 4, pp. 837-845

  10. Response to Monoclonal Antibodies in Asthma: Definitions, Potential Reasons for Failure, and Therapeutic Options for Suboptimal Response

    Journal of investigational allergology & clinical immunology, Vol. 33, Núm. 1, pp. 1-13

  11. Therapeutic Goals and Treatable Traits: Long-Term Trends in a Severe Asthma Population

    Archivos de Bronconeumologia, Vol. 59, Núm. 12, pp. 842-845

  12. Validation of the Asthma Impairment and Risk Questionnaire in Spain: A Useful Tool for Assessing Asthma Control in Adolescents and Adults

    Journal of Investigational Allergology and Clinical Immunology

2022

  1. EAACI position paper on the clinical use of the bronchial allergen challenge: Unmet needs and research priorities

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 77, Núm. 6, pp. 1667-1684

  2. Early Initiation of Corticosteroids Might be Harmful in Patients Hospitalized With COVID-19 Pneumonia: A Multicenter Propensity Score Analysis

    Archivos de Bronconeumologia, Vol. 58, Núm. 3, pp. 281-283

  3. Early Recognition of Low-Risk SARS-CoV-2 Pneumonia: A Model Validated With Initial Data and Infectious Diseases Society of America/American Thoracic Society Minor Criteria

    Chest, Vol. 162, Núm. 4, pp. 768-781